Xencor, Inc Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Xencor, Inc (XNCR) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 656.06 thousand shares for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-05-06
- Xencor, Inc antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 656.06K shares, a 6.31% decline year-over-year.
- Xencor, Inc antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 81.60K shares, a 81.50% decline year-over-year.
- Xencor, Inc antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 69.19K shares, a 86.44% decline year-over-year.
- Xencor, Inc antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 700.26K shares, a 14.30% decline year-over-year.
- Xencor, Inc antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 245.31K shares, a 62.04% decline from fiscal 2024.
- Xencor, Inc antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 646.29K shares, a 40.27% decline from fiscal 2023.
- Xencor, Inc antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 1.08M shares, a 9.56% decline from fiscal 2022.
- Xencor, Inc antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 1.20M shares, a 0.00% change from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|---|
| 2026-03-31 | 656.06K shares 10-Q · filed 2026-05-06 | |||||
| 2025-12-31 | 245.31K shares 10-K · filed 2026-02-25 | |||||
| 2025-09-30 | 81.60K shares 10-Q · filed 2025-11-05 | 260.11K shares 10-Q · filed 2025-11-05 | ||||
| 2025-06-30 | 69.19K shares 10-Q · filed 2025-08-06 | 321.47K shares 10-Q · filed 2025-08-06 | ||||
| 2025-03-31 | 700.26K shares 10-Q · filed 2026-05-06 | |||||
| 2024-12-31 | 646.29K shares 10-K · filed 2026-02-25 | |||||
| 2024-09-30 | 441.14K shares 10-Q · filed 2025-11-05 | 599.15K shares 10-Q · filed 2025-11-05 | ||||
| 2024-06-30 | 510.21K shares 10-Q · filed 2025-08-06 | 670.01K shares 10-Q · filed 2025-08-06 | ||||
| 2024-03-31 | 817.06K shares 10-Q · filed 2025-05-07 | |||||
| 2023-12-31 | 1.08M shares 10-K · filed 2026-02-25 | |||||
| 2022-12-31 | 1.20M shares 10-K/A · filed 2025-02-24 | |||||
| 2022-03-31 | 2.56M shares 10-Q · filed 2023-05-08 | |||||
| 2021-12-31 | 1.20M shares 10-K · filed 2023-02-27 | |||||
| 2021-09-30 | 1.14M shares 10-Q · filed 2022-11-07 | |||||
| 2021-06-30 | 1.37M shares 10-Q · filed 2022-08-03 | 698.92K shares 10-Q · filed 2022-08-03 | ||||
| 2019-12-31 | 1.02M shares 10-K · filed 2022-02-24 | |||||
| 2019-09-30 | 2.27M shares 10-Q · filed 2019-11-05 | 998.19K shares 10-Q · filed 2020-11-06 | ||||
| 2019-06-30 | 1.69M shares 10-Q · filed 2019-08-07 | 1.17M shares 10-Q · filed 2020-08-05 | ||||
| 2019-03-31 | 964.74K shares 10-Q · filed 2020-05-08 | |||||
| 2018-12-31 | 1.88M shares 10-K · filed 2019-02-26 | |||||
| 2018-09-30 | 1.88M shares 10-Q · filed 2019-11-05 | |||||
| 2018-06-30 | 1.93M shares 10-Q · filed 2019-08-07 | 1.77M shares 10-Q · filed 2019-08-07 | ||||
| 2018-03-31 | 1.57M shares 10-Q · filed 2019-05-09 | |||||
| 2017-12-31 | 1.29M shares 10-K · filed 2019-02-26 | |||||
| 2017-03-31 | 1.47M shares 10-Q · filed 2017-05-10 | |||||
| 2016-03-31 | 1.05M shares 10-Q · filed 2017-05-10 | |||||
| 2015-12-31 | 1.36M shares 10-K · filed 2018-02-28 | |||||
| 2015-09-30 | 3.41M shares 10-Q · filed 2015-11-04 | 3.41M shares 10-Q · filed 2015-11-04 | ||||
| 2015-06-30 | 3.41M shares 10-Q · filed 2015-08-05 | 3.41M shares 10-Q · filed 2015-08-05 | ||||
| 2015-03-31 | 3.30M shares 10-Q · filed 2015-05-05 | |||||
| 2014-12-31 | 2.85M shares 10-K · filed 2017-03-01 | |||||
| 2014-09-30 | 1.40M shares 10-Q · filed 2015-11-04 | 1.40M shares 10-Q · filed 2015-11-04 | ||||
| 2014-06-30 | 2.62M shares 10-Q · filed 2015-08-05 | 1.27M shares 10-Q · filed 2014-08-01 | 2.62M shares 10-Q · filed 2015-08-05 | 1.27M shares 10-Q · filed 2014-08-01 | ||
| 2014-03-31 | 2.53M shares 10-Q · filed 2015-05-05 | 1.26M shares 10-Q · filed 2014-05-15 | ||||
| 2013-12-31 | 1.79M shares 10-K · filed 2016-03-08 | |||||
| 2013-09-30 | 1.19M shares 10-Q · filed 2014-11-10 | 1.19M shares 10-Q · filed 2014-11-10 | ||||
| 2013-06-30 | 1.30M shares 10-Q · filed 2014-08-01 | 1.30M shares 10-Q · filed 2014-08-01 | ||||
| 2013-03-31 | 16.31M shares 10-Q · filed 2014-05-15 | |||||
| 2012-12-31 | 16.29M shares 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |